3-Year Results: Sustained Psoriasis Treatment Goals Achieved with Risankizumab

Key Takeaways

• 96.2% of patients achieved NPF-defined acceptable responses after 36 months of risankizumab.
• 86.1% maintained PASI 90 scores from 12 to 36 months.
• 68.8% of patients reported minimal quality-of-life impact (DLQI = 0/1) after 36 months.

New research presented at the 2025 American Academy of Dermatology Annual Meeting showed long-term treatment with risankizumab resulted in sustained skin clearance for most patients with moderate to severe plaque psoriasis.

Researchers for the study followed 179 patients from the CorEvitas Psoriasis Registry over 36 months (among the 179 patients, 40.8% were female, with a mean age of 48.8 years and an average baseline BSA involvement of 14.7%). The research assessed the ability of patients to meet the National Psoriasis Foundation (NPF) treatment targets, which included achieving body surface area (BSA) ≤3% or improving BSA by at least 75% from baseline. The authors assessed the durability of achieving Psoriasis Area and Severity Index (PASI 90) and Dermatology Life Quality Index (DLQI) scores.

After 36 months, 96.2% of patients with baseline BSA > 3 met the NPF criteria, while 84.2% achieved the target response of BSA ≤ 1%. Notably, 68.8% of patients with baseline DLQI > 1 reported a DLQI score of 0/1, reflecting minimal impact on their quality of life.

For those who achieved PASI90 by 12 months, 86.1% maintained this level of skin clearance after 36 months. The study demonstrates that risankizumab, an IL-23 inhibitor, effectively achieves and sustains high treatment targets in real-world clinical settings.

"Most patients in a real-world setting, with 36 months of persistent treatment with risankizumab, achieved NPF-defined treatment targets and maintained high skin clearance," the authors concluded.